- Company
- Tabrecta can be prescribed at hospitals
- by Eo, Yun-Ho Jul 14, 2022 05:54am
- According to related industries, Tabrecta of Novartis Korea passed the D.C. of medical institutions such as the National Cancer Center, Pusan National University Hospital, Samsung Seoul Hospital, and Sinchon Severance Hospital. Tabrecta, which is currently undergoing the insurance benefit registration process, was approved in Korea in Novembe
- Company
- SK Bioscience, "SKY Covione booster prevents Omicron”
- by Chon, Seung-Hyun Jul 14, 2022 05:54am
- SK Bioscience announced on the 13th that its ‘SKYCovione’ has shown to have an effect in preventing the Omicron variant as a booster shot. The company identified such results from an extension study on Phase I/II trial on SKYCovione that was conducted on 81 healthy adults who received a booster dose of SKYCovione around 7 months after p
- Company
- Indications of Jardiance have expanded
- by Jul 13, 2022 06:05am
- As the SGLT-2 inhibitor Jardiance expanded its scope to a treatment for chronic heart failure unrelated to heart rate, expectations were also expressed in the clinical field. The medical staff said, "We changed the paradigm of heart failure treatment. There are also non-payment areas, but the burden of drug prices is low, so we are actively u
- Company
- J&J will spin off its consumer health division next year
- by Eo, Yun-Ho Jul 13, 2022 06:05am
- Johnson & Johnson will officially spin off its Consumer Health division in the first half of next year. According to industry sources, Johnson & Johnson Korea’s Consumer Health division, which is in charge of cosmetics and the OTC drug business, will be spun off into a separate corporation in the first half of 2023. In line with the meas
- Company
- Pharmbio's Orafang was published in the JCC
- by Nho, Byung Chul Jul 13, 2022 06:05am
- Pharmbio (Chairman Nam Bong-gil) announced on the 12th that the comparative clinical results on the use of Orafang PO and 2L PEG drugs for IBD patients in Ccaid were introduced in the famous journal Journal of Cron's and Colitis. JCC is an SCIE-class medical journal in the field of inflammatory bowel disease published by Oxford University
- Company
- Will Godex overcome its reimb crisis at half price?
- by Nho, Byung Chul Jul 13, 2022 06:05am
- Celltrion Pharm’s Godex cap, which was not recognized for its reimbursement adequacy and rejected reimbursement by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee on the 7th, is drawing attention due to the possibility of receiving a reimbursement cut rather than a reimbursement deletion decisio
- Company
- Vyzulta reimbursed and prescribed at general hospitals
- by Eo, Yun-Ho Jul 12, 2022 05:53am
- The glaucoma treatment ‘Vyzulta’ has received approval for insurance benefits and is landing at general hospitals in Korea. According to industry sources, Baush + Lomb Korea’s ophthalmic solution Vyzulta (latanoprostene bunod) has passed the drug committees of various medical institutions including the Seoul National University Hospital
- Company
- Johnson & Johnson Medical Devices changed its name
- by Eo, Yun-Ho Jul 12, 2022 05:53am
- Johnson & Johnson Medical of Korea announced a new start with a change of name. The company held a press conference explaining the "J&J MedTech" rebranding at The Plaza Hotel in Jung-gu, Seoul on the 11th and announced its vision to lead innovation in the future medical market combined with digital as a global leading company. Johnson &
- Company
- NPS buys Samsung Biologics and SD Biosensor shares
- by Kim, Jin-Gu Jul 12, 2022 05:52am
- In the midst of the prolonged contraction observed in the Korean stock market, Korea’s largest institutional investor, the National Pension Service (NPS), was found to have expanded its investment in biotech/pharma companies by nearly &8361;500 billion. NPS net purchased &8361;140 billion worth of Samsung Biologics shares and increased
- Company
- Will Celltrion Pharmaceutical voluntarily cut down on Godex?
- by Nho, Byung Chul Jul 12, 2022 05:52am
- Celltrion Pharmaceutical's Godex is on the verge of being expelled from insurance registration, and it is expected to cut voluntary drug prices at the level of comparative drugs as the last defense measure to maintain benefits. The reason why Celltrion Pharmaceutical's strategy is drawing attention is that if Godex, which looks like 60 billio
